Ciaran N Kohli-Lynch1, Brandon K Bellows2, Yiyi Zhang2, Bonnie Spring3, Dhruv S Kazi4, Mark J Pletcher5, Eric Vittinghoff5, Norrina B Allen3, Andrew E Moran6. 1. Division of General Medicine, Columbia University Irving Medical Center, New York, New York, USA; Center for Health Services and Outcomes Research, Northwestern University, Chicago, Illinois, USA; Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, United Kingdom. 2. Division of General Medicine, Columbia University Irving Medical Center, New York, New York, USA. 3. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 4. Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 5. Department of Epidemiology and Biostatistics, University of California-San Francisco School of Medicine, San Francisco, California, USA. 6. Division of General Medicine, Columbia University Irving Medical Center, New York, New York, USA. Electronic address: aem35@cumc.columbia.edu.
Abstract
BACKGROUND: Raised low-density lipoprotein cholesterol (LDL-C) in young adulthood (aged 18-39 years) is associated with atherosclerotic cardiovascular disease (ASCVD) later in life. Most young adults with elevated LDL-C do not currently receive lipid-lowering treatment. OBJECTIVES: This study aimed to estimate the prevalence of elevated LDL-C in ASCVD-free U.S. young adults and the cost-effectiveness of lipid-lowering strategies for raised LDL-C in young adulthood compared with standard care. METHODS: The prevalence of raised LDL-C was examined in the U.S. National Health and Nutrition Examination Survey. The CVD Policy Model projected lifetime quality-adjusted life years (QALYs), health care costs, and incremental cost-effectiveness ratios (ICERs) for lipid-lowering strategies. Standard care was statin treatment for adults aged ≥40 years based on LDL-C, ASCVD risk, or diabetes plus young adults with LDL-C ≥190 mg/dL. Lipid lowering incremental to standard care with moderate-intensity statins or intensive lifestyle interventions was simulated starting when young adult LDL-C was either ≥160 mg/dL or ≥130 mg/dL. RESULTS: Approximately 27% of ASCVD-free young adults have LDL-C of ≥130 mg/dL, and 9% have LDL-C of ≥160 mg/dL. The model projected that young adult lipid lowering with statins or lifestyle interventions would prevent lifetime ASCVD events and increase QALYs compared with standard care. ICERs were US$31,000/QALY for statins in young adult men with LDL-C of ≥130 mg/dL and US$106,000/QALY for statins in young adult women with LDL-C of ≥130 mg/dL. Intensive lifestyle intervention was more costly and less effective than statin therapy. CONCLUSIONS: Statin treatment for LDL-C of ≥130 mg/dL is highly cost-effective in young adult men and intermediately cost-effective in young adult women.
BACKGROUND: Raised low-density lipoprotein cholesterol (LDL-C) in young adulthood (aged 18-39 years) is associated with atherosclerotic cardiovascular disease (ASCVD) later in life. Most young adults with elevated LDL-C do not currently receive lipid-lowering treatment. OBJECTIVES: This study aimed to estimate the prevalence of elevated LDL-C in ASCVD-free U.S. young adults and the cost-effectiveness of lipid-lowering strategies for raised LDL-C in young adulthood compared with standard care. METHODS: The prevalence of raised LDL-C was examined in the U.S. National Health and Nutrition Examination Survey. The CVD Policy Model projected lifetime quality-adjusted life years (QALYs), health care costs, and incremental cost-effectiveness ratios (ICERs) for lipid-lowering strategies. Standard care was statin treatment for adults aged ≥40 years based on LDL-C, ASCVD risk, or diabetes plus young adults with LDL-C ≥190 mg/dL. Lipid lowering incremental to standard care with moderate-intensity statins or intensive lifestyle interventions was simulated starting when young adult LDL-C was either ≥160 mg/dL or ≥130 mg/dL. RESULTS: Approximately 27% of ASCVD-free young adults have LDL-C of ≥130 mg/dL, and 9% have LDL-C of ≥160 mg/dL. The model projected that young adult lipid lowering with statins or lifestyle interventions would prevent lifetime ASCVD events and increase QALYs compared with standard care. ICERs were US$31,000/QALY for statins in young adult men with LDL-C of ≥130 mg/dL and US$106,000/QALY for statins in young adult women with LDL-C of ≥130 mg/dL. Intensive lifestyle intervention was more costly and less effective than statin therapy. CONCLUSIONS: Statin treatment for LDL-C of ≥130 mg/dL is highly cost-effective in young adult men and intermediately cost-effective in young adult women.
Authors: Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah Journal: J Am Coll Cardiol Date: 2018-11-10 Impact factor: 24.094
Authors: Rui Li; Shuli Qu; Ping Zhang; Sajal Chattopadhyay; Edward W Gregg; Ann Albright; David Hopkins; Nicolaas P Pronk Journal: Ann Intern Med Date: 2015-09-15 Impact factor: 25.391
Authors: Naveed Sattar; David Preiss; Heather M Murray; Paul Welsh; Brendan M Buckley; Anton J M de Craen; Sreenivasa Rao Kondapally Seshasai; John J McMurray; Dilys J Freeman; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G Westendorp; James Shepherd; Barry R Davis; Sara L Pressel; Roberto Marchioli; Rosa Maria Marfisi; Aldo P Maggioni; Luigi Tavazzi; Gianni Tognoni; John Kjekshus; Terje R Pedersen; Thomas J Cook; Antonio M Gotto; Michael B Clearfield; John R Downs; Haruo Nakamura; Yasuo Ohashi; Kyoichi Mizuno; Kausik K Ray; Ian Ford Journal: Lancet Date: 2010-02-16 Impact factor: 79.321
Authors: Donald M Lloyd-Jones; Eric P Leip; Martin G Larson; Ralph B D'Agostino; Alexa Beiser; Peter W F Wilson; Philip A Wolf; Daniel Levy Journal: Circulation Date: 2006-02-06 Impact factor: 29.690
Authors: Bonnie Spring; Angela F Pfammatter; Sara H Marchese; Tammy Stump; Christine Pellegrini; H Gene McFadden; Donald Hedeker; Juned Siddique; Neil Jordan; Linda M Collins Journal: Obesity (Silver Spring) Date: 2020-07-12 Impact factor: 5.002
Authors: Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats Journal: JAMA Date: 2016-09-13 Impact factor: 56.272
Authors: Norrina B Allen; Juned Siddique; John T Wilkins; Christina Shay; Cora E Lewis; David C Goff; David R Jacobs; Kiang Liu; Donald Lloyd-Jones Journal: JAMA Date: 2014-02-05 Impact factor: 157.335
Authors: Dhruv Mahtta; David J Ramsey; Mahmoud Al Rifai; Khurram Nasir; Zainab Samad; David Aguilar; Hani Jneid; Christie M Ballantyne; Laura A Petersen; Salim S Virani Journal: JAMA Netw Open Date: 2020-08-03
Authors: Thomas O'Toole; Michelle D Kelsey; Nishant P Shah; Robert W McGarrah; Neha J Pagidipati Journal: Curr Cardiol Rep Date: 2022-08-25 Impact factor: 3.955
Authors: Ciaran N Kohli-Lynch; James Lewsey; Kathleen A Boyd; Dustin D French; Neil Jordan; Andrew E Moran; Naveed Sattar; David Preiss; Andrew H Briggs Journal: Circulation Date: 2022-03-07 Impact factor: 39.918